drugset / Trial / NCT06700720
YN001-004 in Patients With Coronary Atherosclerosis in Australia
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
Timeline
- Start
- 2026-02
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YN001 | Unknown | — | Intravenous |
| Background | Evolocumab | Monoclonal antibody | 140 mg | Subcutaneous |